Day: December 6, 2019

Highlights:Beter Beheer B.V., the wholly owned subsidiary of Beter Bed Holding, has entered into two separate sale-and-leaseback transactions for its properties in Hoogeveen and Nieuw-Vennep for a cash consideration of in total € 5.1 million. The total book profit on these transactions is circa € 1.6 million after tax.Together with the previously announced sale-and-leaseback transaction of the property in Uden (Linie 27), these transactions show that the Benelux operations of Beter Bed Holding will continue operating in its current logistical structure.These transactions contribute to the improvement of the net debt position of Beter Bed Holding, because the proceeds will be used to repay bank debt. Together with the divestment of Matratzen Concord that was completed on 2 December, these transactions are important steps for the transformation...

ANCHORAGE, Alaska, Dec. 06, 2019 (GLOBE NEWSWIRE) — Northrim BanCorp, Inc. (NASDAQ: NRIM) today announced that the Board of Directors declared a regular quarterly cash dividend of $0.33 per share. The dividend will be payable on December 27, 2019, to shareholders of record at the close of business on December 19, 2019.“We are committed to providing returns to our shareholders through earnings growth, building equity, and paying reliable dividends,” said Joe Schierhorn, President and CEO. At the stock price of $36.67 per share at the close of the market on December 5, 2019, the current dividend equates to a yield of 3.60% on an annualized basis.On October 28, 2019, Northrim reported earnings of $7.5 million, or $1.11 per diluted share, for the third quarter of 2019. Return on average assets was 1.90%, return on average equity was...

DALLAS, Dec. 06, 2019 (GLOBE NEWSWIRE) — Primoris Services Corporation (NASDAQ Global Select: PRIM) (“Primoris” or “Company”) today announced two new engineering awards with a combined value over $34 million.  The contracts were secured by OnQuest, part of the Power, Industrial, & Engineering segment. The first award is for engineering and procurement of four world-class arbor type heaters as part of a grass-root Propylene Dehydration Project in Alberta, Canada.  In addition to the heaters, OnQuest will be designing and supplying the integrated Burner Management System for the heaters.The second award is for engineering, procurement and fabrication to retube two crude heaters, including replacement convection modules, and retube the CCR heater located in an existing refinery in Illinois.Work is scheduled to commence in the fourth...

KANSAS CITY, Mo., Dec. 06, 2019 (GLOBE NEWSWIRE) — H&R Block’s (NYSE: HRB) DIY Online tax products are now available at hrblock.com and in the Apple and Google Play stores, offering an easy, cost-effective way to do your own taxes. H&R Block’s award-winning online products are a great value in tax prep, starting with free, with all products typically priced at least $10 less than TurboTax. For DIY filers who want the care and extra help from a tax expert, H&R Block Online AssistSM is available in early January, offering unlimited, on-demand chat sessions, with a highly trained H&R Block tax expert, IRS enrolled agent or CPA.More for less with H&R Block Online, including free

SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) — Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to APVO436, a bispecific antibody candidate intended for the treatment of acute myelogenous leukemia (AML). APVO436 is currently being evaluated in a Phase 1/1b clinical trial in patients with AML and myelodysplastic syndrome (MDS).The U.S. Orphan Drug Act is intended to encourage companies to develop safe and effective therapies for the treatment of rare diseases and conditions, specifically those expected to affect fewer than 200,000 people in the United States. Orphan drug designation provides important benefits to companies such as eligibility for...

DALLAS, Dec. 06, 2019 (GLOBE NEWSWIRE) — Rocky Mountain High Brands, Inc. (OTCQB: RMHB), a healthy lifestyle Company specializing in high-quality health and wellness products, announced today it has signed a distribution agreement with D.B. Miller, Inc., dba Austin Beverage Company, further expanding its disruptive HEMPd beverages, infused with 20 mg. of hemp extract, throughout Central Texas.Founded in 2000, Austin Beverage Company (“Austin Beverage”) distributes a comprehensive portfolio of non-alcoholic, premium beverage brands including Coco Joy, Crystal Geyser, Celsius, Bawls, Super Coffee and Wave Soda together with their own TEXAS TEA®, TEXAS SQUEEZE®, TEXAS mADE® and Busy Bee Yerba Mate brands to retail accounts throughout Central Texas. The agreement with Austin Beverage will enable further discussion between our companies...

BEIJING, Dec. 06, 2019 (GLOBE NEWSWIRE) — Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, hemp products, and various health and well-being focused plant-based products in China, announced today that it completed its first board meeting (the “Meeting”) for fiscal year 2019 held on November 26, 2019 in Beijing, China and pursuant to which the Company’s directors:Re-elected Mr. Yuying Zhang as the Chairman of the Board of Company to hold office until the next annual general meeting.Elected Mr. Baolin Li as the Vice Chairman of the Board of Company to hold office until the next annual general meeting.Elected Mr. Harry Edelson as an independent director of the Board of Company.Mr. Harry Edelson has worked...

GERMANTOWN, Md., Dec. 06, 2019 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary Masthercell Global, Inc., as well as localized point-of-care (“POCare”) development and processing centers for therapeutic treatments, today announced a strategic partnership agreement (“Partnership”) between the HYGEIA Group and the Theracell–Orgenesis joint venture (“JV”).  Under the Agreement, the JV will implement Orgenesis’ POCare cell therapy platform for clinical development and commercialization of cell and gene therapies within HYGEIA Group’s network of three hospitals in Greece. As previously announced, Orgenesis and TheraCell Advanced Biotechnology formed a JV to advance Orgenesis’...

ProVen Growth and Income VCT plcIssue of Equity (DRIS)6 December 2019